🟢 Gossamer Bio is trading 5.7% up — no clear company-specific catalyst identified

Gossamer Bio is trading at $12.24, up +5.70%, with no clear company-specific catalyst identified for the move.

• No clear company-specific announcement or catalyst dated September 30 was identified.
• The seralutinib FDA application submission was announced September 23, so it is not a new event today.
• Broader indexes are higher and may support the move, but evidence does not establish that macro sentiment directly explains the gain; confidence is low.